mefloquine has been researched along with Breast Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Petasis, NA; Schönthal, AH; Sharma, N; Thomas, S | 1 |
1 review(s) available for mefloquine and Breast Neoplasms
Article | Year |
---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for mefloquine and Breast Neoplasms
Article | Year |
---|---|
Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent.
Topics: Antimalarials; Autophagy; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mefloquine; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ubiquitination | 2012 |